✦ LIBER ✦

A phase II trial of paclitaxel in refractory germ cell tumors

✍ Scribed by Alan B. Sandler; Antonios Cristou; Susan Fox; Stephen D. Williams; Craig R. Nichols; Martine Turns; Bruce J. Roth

Publisher: John Wiley and Sons
Year: 1998
Tongue: English
Weight: 78 KB
Volume: 82
Category: Article
ISSN: 0008-543X
DOI: 10.1002/(sici)1097-0142(19980401)82:7<1381::aid-cncr23>3.0.co;2-1

No coin nor oath required. For personal study only.

✦ Synopsis

over 24 hours every 21 days without growth factor support. The median age of the patients was 32.5 years (range, 18-49 years). The testis was the primary site of Genitourinary Oncology Program, Indiana Unitumor for 13 patients (72%) and the tumor was extragonadal in 5 patients (28%).

📜 SIMILAR VOLUMES

Hyperthermia for the treatment of patien

Hyperthermia for the treatment of patients with malignant germ cell tumors : A Phase I/II study in ten children and adolescents with recurrent or refractory tumors

✍ Rüdiger Wessalowski; Heidi Kruck; Hildegard Pape; Thomas Kahn; Reinhart Willers; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 3 views

waves in combination with platinum-based chemotherapy in ten children and 4 Institute of Statistics, Heinrich-Heine Univeradolescents with recurrent or refractory GCTs. sity, Du ¨sseldorf, Germany. ## RESULTS. Seven of ten patients with recurrent or refractory GCTs had objective responses. Of the

Recent advances in management of patient

Recent advances in management of patients with platinum-refractory testicular germ cell tumors

✍ Christian Kollmannsberger; Craig Nichols; Carsten Bokemeyer 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 1 views

Southwest oncology group phase II study

Southwest oncology group phase II study of arsenic trioxide in patients with refractory germ cell malignancies

✍ Tomasz M. Beer; Catherine M. Tangen; Craig R. Nichols; Kim A. Margolin; Robert D 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 2 views

A phase I trial of ifosfamide and paclit

A phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors

✍ Craig A. Bunnell; Lynn Thompson; Lori Buswell; Ross Berkowitz; Michael Muto; Ell 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 2 views

## Background: Ifosfamide and paclitaxel are antineoplastic agents with broad activity and with different mechanisms of action. a phase i trial was conducted to determine the maximum tolerated dose and associated toxicities of these agents when used in combination. ## Methods: Patients with refra

Phase II trial of paclitaxel, estramusti

Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma

✍ David C. Smith; Christopher H. Chay; Rodney L. Dunn; Jude Fardig; Peg Esper; Kar 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 1 views

## Abstract ## BACKGROUND Preclinical data suggest that the combination of intravenous (i.v.) paclitaxel, carboplatin, oral etoposide, and oral estramustine (TEEC) has significant activity in patients with advanced, hormone‐refractory prostate carcinoma. The authors conducted this clinical trial t

A Phase II trial of gemcitabine for meta

A Phase II trial of gemcitabine for metastatic neuroendocrine tumors

✍ Matthew H. Kulke; Haesook Kim; Jeffrey W. Clark; Peter C. Enzinger; Thomas J. Ly 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

## Abstract ## BACKGROUND Treatment with traditional cytotoxic chemotherapy regimens containing streptozocin or dacarbazine has resulted in only marginal benefit for patients with metastatic neuroendocrine tumors. The use of these regimens has been further limited by their potential toxicity. Gemc